RZLT Rezolute, Inc.
Price Chart
Executive Summary
Rezolute announced positive interim data from its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. 6 of 8 enrolled participants met the primary endpoint (≥50% reduction in IV glucose requirements), and all 6 achieved complete discontinuation of IV glucose. The study is 50% enrolled (8 of 16 planned participants), and topline results are expected in H2 2026. One participant withdrew for hospice care and is counted as a non-responder; no drug-related adverse events were reported.
Actionable Insight
The interim data strongly de-risks the upLIFT study and supports ersodetug's efficacy in tumor HI, a registrational path. Traders should watch for full enrollment and topline results in H2 2026, as well as FDA engagement on the congenital HI path forward. The 75% analyst bullish consensus and $348M market cap suggest the stock may re-rate on this positive catalyst.
Key Facts
- 6 of 8 enrolled participants met the primary endpoint (≥50% reduction in IV glucose requirements within 8-week pivotal treatment phase)
- All 6 responders achieved complete discontinuation of intravenous glucose requirements
- Study is 50% enrolled (8 of 16 planned participants); topline results expected H2 2026
- One participant withdrew for hospice care (Stage 4 metastatic colon cancer, ECOG 4) and is counted as a non-responder
- No drug-related adverse events or safety findings reported to date
- All participants completing the 8-week pivotal period elected to continue into the open-label extension (up to 6 months cumulative treatment)
Financial Impact
No financial figures provided in the filing. The positive interim data supports the drug's efficacy signal in tumor HI, a rare disease with high unmet need, and may increase the probability of regulatory success and commercial value.
Risk Factors
- Small sample size (8 participants) limits statistical reliability; one non-responder due to hospice withdrawal could raise questions about patient selection
- Topline results in H2 2026 may differ from interim data
- FDA path for congenital HI remains uncertain after the sunRIZE study miss
- Competing therapies or regulatory setbacks could limit commercial opportunity
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-069206 |
| Document: tm2616579d1_ex99-1.htm | 0001104659-26-069206 |
| Document: 0001104659-26-069206-index-headers.html | 0001104659-26-069206 |
| Document: 0001104659-26-069206-index.html | 0001104659-26-069206 |
| Document: 0001104659-26-069206.txt | 0001104659-26-069206 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
2d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
Jun 2, 2026
4d ago
|
8-K
| $4.00 $4.58 | ▲ +14.50% | ▲ +15.19% | $4.25 (+6.25%) |
|
May 12, 2026
25d ago
|
8-K
| $3.33 $3.33 | · 0.00% | ▲ +0.00% | $4.25 (+27.63%) |
|
May 12, 2026
25d ago
|
Press Release
| $3.33 $3.33 | · 0.00% | ▼ −0.00% | $4.25 (−27.63%) |
|
May 1, 2026
5w ago
|
Press Release
| $3.30 $3.30 | · 0.00% | ▲ +0.34% | $4.25 (+28.79%) |
|
Apr 21, 2026
6w ago
|
Press Release
| $3.28 $3.33 | ▼ −1.52% | ▼ −0.51% | $4.25 (−29.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access